Pasireotide sub-cutaneous formulation + Pasireotide lon acting release formulation
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Melanoma and Merkel Cell Carcinoma
Conditions
Metastatic Melanoma and Merkel Cell Carcinoma
Trial Timeline
Nov 1, 2012 → Apr 1, 2015
NCT ID
NCT01652547About Pasireotide sub-cutaneous formulation + Pasireotide lon acting release formulation
Pasireotide sub-cutaneous formulation + Pasireotide lon acting release formulation is a phase 1 stage product being developed by Novartis for Metastatic Melanoma and Merkel Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01652547. Target conditions include Metastatic Melanoma and Merkel Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Melanoma and Merkel Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01652547 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Melanoma and Merkel Cell Carcinoma